Insulet Stock News

ACTON, Mass.--(BUSINESS WIRE)--Headline of release should read: Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 (instead of Insulet to Announce Fourth Quar

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced

Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.

Investors are optimistic about Insulet's (PODD) better-than-expected revenues and solid revenue growth across the Omnipod product line.

Private Advisor Group LLC cut its stake in shares of Insulet Co. (NASDAQ:PODD) by 10.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,700 shares of the medical instruments suppliers stock after selling 200 shares during the period. Private []

Insulet (NASDAQ:PODD)s stock had its buy rating restated by stock analysts at SVB Leerink in a report released on Tuesday, Price Targets.com reports. Several other brokerages have also weighed in on PODD. Canaccord Genuity increased their price objective on Insulet from $300.00 to $330.00 and gave the stock a buy rating in a research report []

SVB Leerink reiterated their buy rating on shares of Insulet (NASDAQ:PODD) in a research note issued to investors on Tuesday, PriceTargets.com reports. A number of other brokerages have also recently issued reports on PODD. Canaccord Genuity lifted their price objective on Insulet from $300.00 to $330.00 and gave the company a buy rating in a []

The conventional treatments for amblyopia include deflective correction, obstruction, and atropine penalization. Optimum refractive improvement alone can resolution in at least one-third of cases with crude anisometropic amblyopia and even some unprocessed strabismic amblyopia. All actions for amblyopia are based

The highly anticipated launch of the Insulet (NSDQ:PODD) Omnipod 5 may not come as soon as thought as an FDA review drags on. SeekingAlpha reported that Insulet CEO Shacey Petrovic, speaking at the Nasdaq Investor Conference, said the regulatory agency will likely not complete its review of the next-generation Omnipod 5 before the end of [] The post Report: Insulet expects delays in FDA review for Omnipod 5 with launch pushed back appeared first on Drug Delivery Business .

This past Friday two events spooked the diabetes device world. The first was news that Abbott filed an IP lawsuit against Dexcom, the second Insulet announced the OmniPod 5 approval would not come before the end of 2021 more likely sometime in the first quarter The post These things happen appeared first on Diabetic Investor .

Equities research analysts expect Insulet Co. (NASDAQ:PODD) to post $0.31 earnings per share for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for Insulets earnings, with the highest EPS estimate coming in at $0.37 and the lowest estimate coming in at $0.23. Insulet reported earnings of ($0.26) per share in the []

Equities analysts forecast that Insulet Co. (NASDAQ:PODD) will report earnings per share (EPS) of $0.31 for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Insulets earnings. The highest EPS estimate is $0.37 and the lowest is $0.23. Insulet posted earnings of ($0.26) per share during the same quarter last year, []